Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Completed · Phase 1/Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for recurrent glioma and meningioma. PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate in treating patients who have progressive, recurrent, or unresectable malignant glioma or meningioma.

Key facts

Study ID: NCT00010049
Run by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed: 105
Starts: 2001-02-27
Expected to finish: 2006-08-15
Last updated by the study team: 2018-06-27

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
UCSF Comprehensive Cancer Center — San Francisco, California, United States
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.